GL
GLSHQ.US Gelesis Holdings, Inc.
- Market cap
- USD 7.33K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is GLSHQ.US undervalued?
Graham numberThe Graham number of Gelesis Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gelesis Holdings, Inc. fundamental analysis
No fundamental analysis for Gelesis Holdings, Inc. yet.
Gelesis Holdings, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gelesis Holdings, Inc.
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver diseas…
Full company profileGelesis Holdings, Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gelesis Holdings, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | - | 11.2M | 25.8M | 5.72M |
| Gross Profit | - | 1.20M | -1.79M | 2.25M |
| Operating Income | - | -85.0M | -122M | -43.9M |
| EBITDA | -12.5M | -88.2M | -48.3M | -13.4M |
| Net Income | -15.3M | -93.7M | -57.1M | -25.9M |
| EPS | -0.44 | -16 | -0.81 | -0.35 |
| Balance Sheet | ||||
| Total Assets | 277M | 146M | 103M | 95.9M |
| Total Liabilities | 41.4M | 146M | 116M | 115M |
| Shareholders' Equity | 235M | -330M | -25.1M | -31.5M |
| Cash & Short-term Investments | 492K | 28.4M | 7.41M | 7.91M |
| Total Debt | - | 66.3M | 62.3M | 61.9M |
| Cash Flow | ||||
| Operating Cash Flow | -861K | -55.3M | -77.7M | -16.2M |
| Capital Expenditure | 0.00 | 19.9M | 9.12M | 484K |
| Free Cash Flow | -861K | -75.2M | -86.8M | -16.6M |
| Ratios | ||||
| ROE | -6.5% | - | - | - |
| ROA | -5.5% | -64.1% | -55.3% | -27.0% |
| Net Profit Margin | - | -837.9% | -221.7% | -452.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gelesis Holdings, Inc. dividends
Gelesis Holdings, Inc. has not paid dividends in the last 3 fiscal years.
Who owns Gelesis Holdings, Inc.
Ownership data of Gelesis Holdings, Inc. is not available yet.
Gelesis Holdings, Inc. company profile
- Company name
- Gelesis Holdings, Inc.
- Ticker
- GLSHQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 93
- Fiscal year end
- December
- Address
- 501 Boylston Street, Boston, MA, United States, 02116
- Phone
- 617 456 4718
- Website
- gelesis.com
About Gelesis Holdings, Inc.
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Gelesis Holdings, Inc. management
2- Dr. Alessandro Sannino Ph.D.Co-Inventor & Lead Project Scientist · born 1972
- Ms. Joy Bauer M.S., RDNChief Nutrition Officer of Plenity